TRAVERE THERAPEUTICS, INC. Impairment of Retained Interest
TRAVERE THERAPEUTICS, INC. (TVTX) reported Impairment of Retained Interest of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfRetainedInterest · last filed 2022-02-24
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for the quarter ending 2020-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for the quarter ending 2019-12-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for the quarter ending 2019-09-30 was $15.00M.
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for fiscal 2021 was $0.00.
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for fiscal 2019 was $15.00M.
- TRAVERE THERAPEUTICS, INC. impairment of retained interest for fiscal 2018 was $0.00.
| Period end | Impairment of Retained Interest 1 month | Impairment of Retained Interest 3 month | Impairment of Retained Interest 6 month | Impairment of Retained Interest 9 month | Impairment of Retained Interest 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | ||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $15.00M derived: sum of 2 quarters · filed 2022-02-24 | $15.00M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $15.00M 10-K · filed 2021-03-01 | $15.00M 10-Q · filed 2020-11-05 | |||
| 2019-08-31 | $15.00M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |